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Thigh Echymosis in a Newborn
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ABSTRACT
Background and aim: Protein C is one of the important components 
in haemostasis system and its deficiency could increase the risk 
of thromboembolic events. This deficiency is seen in 0.2% of the 
general population. In this case report we present a 3-day old 
neonate with an echymosis in her left thigh.
Case presentation: A female neonate was visited regards to an 
echymotic lesion in her left thigh and a lighter one in the right which 
was present at birth. In her laboratory tests, protein C reported 
17% while her parents had normal level. She was treated with anti-
thrombotics and level of protein C elevated to 73% at discharge.
Conclusion: Clinical manifestations of protein C deficiency could 
be severe and life threatening, so quick and careful management 
is needed.
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INTRODUCTION
Protein C and S systems are the major regulatory systems of 
haemostasis. These are vitamin K dependent pro enzymes which 
are synthesized in the liver. The thrombin thrombo modulin complex 
on the surface of the endothelial cells is the site for the interaction 
with protein C and S. After binding to these complexes, protein 
C becomes activated and protein S acts as a co-factor in this 
process. Activated protein C inhibits factor VIIIa and factor Va, thus 
exhibiting its anticoagulant property and it also enhances fibrinolysis 
through the inhibition of the plasminogen activator inhibitor [1]. 
Individuals with a mutation in the protein C gene tend to have an 
increased risk of thromboembolism. Homozygous or compound 
heterozygous mutants in patients who develop purpura fulminans 
in the neonatal period are rare [2]. 
Clinically, the patients with the protein C and protein S deficiencies 
are at an increased risk for venous thromboembolic disease, occa-
sional arterial thrombosis, neonatal purpura fulminans, childhood 
stroke and even portal vein thrombosis [1].
The protein C deficiency is present in approximately 0.2% of the 
total population. This rate includes asymptomatic people and pati-
ents with severe thrombotic disease. People with the heterozygous 
form of the disease can usually live all their life without clinical 
problems [3]. 
CASe pReSeNTATION
Here, we present a 3-days-old female baby who was delivered by 
vaginal delivery. She was the second baby from a third pregnancy. 
The second one was lost in the first trimester. There was a family 
relationship between the parents (they were cousins). She had no 
remarkable past medical history except for the beginning of jaundice 
from the second day of life. Her birth weight was 3200 grams, her 
present weight was 2900 grams, her head circumference was 34 
cm and her height was 51 cm. 
A bilirubin of 12.5 mg/dl (Normal range =  0.5-1.5 mg/dl) was 
Case Report
reported at first. No poor feeding or abnormal stool or urine were 
detected. An echymosis of about 4 × 7 cm2 had been noticed 
on her left thigh, “which was very light in colour at birth with a 
hand-size” her mother said. There was also a lighter lesion on the 
right thigh. Cutaneous and sub-cutaneous necrosis was noticed 
on her left thigh, plus a mild icter up to the abdomen in her physical 
examination. Antibiotics (Vancomycin, Ceftazidim and Amikacin) 
were started from the first day of her life and they were given for 
20 days. 
The first laboratory tests were as followings: Platelet = 64000, 
PT = 16 sec (PT control = 12 sec), INR =  1.7, 
PTT = 36 Sec (Normal range = 30-45 sec), G6PD = sufficient, 
MBG = B+, NBG = O+ 
Neonate Protein C = 17% and Protein S = 40% 
Father and Mother: Protein C = 98%
A daily transfusion of fresh frozen plasma (FFP) was started from 
the third day of life for about 2 weeks, and then it was changed to 
every single day for 2 other weeks. The platelets reached a level 
[Table/Fig-1]: Thigh showing the lesion
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life, causing tissue necrosis and gangrenous and disseminated 
intravascular coagulation [3].
Abnormalities of antithrombin and the protein C system have been 
documented in association with spontaneous neonatal thrombotic 
problems. The protein C levels gradually improve during life. The 
protein C concentration is 15% of the adult levels during infanthood, 
35% of the adult levels in the premature newborn, 80% of the adult 
levels in adolescents and it improves by 4% every 10 years [3].
Management of these patients with deep vein thrombosis is done 
with heparin anticoagulation, either conventional or low molecular 
weight, along with a protein C concentrate or fresh frozen plasma 
therapy. The patients are advised to avoid dehydration at any cost 
as a preventive measure [1].
Treatment of a patient with protein C deficiency depends on the 
individual patient’s risk of thromboembolic disease. As a result, the 
treatment is based on providing a source of Protein C. This can be 
done with fresh frozen plasma (FFP) or with human plasma protein 
C concentrate. At this time, there are still no studies that compare 
the use of the protein C concentrates versus FFP in severe protein 
C deficiency which is related to thrombosis [3].
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[Table/Fig-2]:  Lesion at discharge 
of 151000 after that. Vitamin K was prescribed concurrently. After 
transferring her to the Oncology Department, the daily Warfarin 
tablet (0.4 mg/ day) was continued with an increasing dose, which 
achieved upto 0.8 mg/ day at discharge. Protein C was reported to 
be 73% at discharge. Debridement of the necrotic area was done a 
day before discharge and the scar continued to heal.
CONClUSIONS 
The classical neonatal manifestation of homozygous protein C 
deficiency is a severe form of thrombosis of the large vessels or 
a purpura fulminans that occurs within a few hours or days of 
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